scholarly journals Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model

2017 ◽  
Vol 31 (7) ◽  
pp. 3138-3149 ◽  
Author(s):  
Giovanna Sociali ◽  
Mirko Magnone ◽  
Silvia Ravera ◽  
Patrizia Damonte ◽  
Tiziana Vigliarolo ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Tolerance ◽  
Mouse Model ◽  
Diabetes Mouse

Structural analysis of tooth and jawbone in a type 2 diabetes mouse model

2014 ◽  
Author(s):  
Silvia Pabisch ◽  
Tsuguno Yamaguchi ◽  
Yasushi Koike ◽  
Kenji Egashira ◽  
Shinsuke Kataoka ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Structural Analysis ◽  
Mouse Model ◽  
Diabetes Mouse

scholarly journals Porphyromonas gingivalis induces entero-hepatic metabolic derangements with alteration of gut microbiota in a type 2 diabetes mouse model

2021 ◽  
Author(s):  
Yoichiro Kashiwagi ◽  
Syunsuke Aburaya ◽  
Naoyuki Sugiyama ◽  
Yuki Narukawa ◽  
Yuta Sakamoto ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Mouse Model ◽  
Gut Microbiota ◽  
Porphyromonas Gingivalis ◽  
Alveolar Bone ◽  
Periodontal Pathogens ◽  
Periodontal Infection ◽  
Related Enzyme ◽  
Diabetes Mouse

Abstract Periodontal infection is thought to generate systemic inflammation, thus aggravating diabetes. Furthermore, orally administered periodontal pathogens may directly alter the gut microbiota. To elucidate this, using an obese db/db diabetes mice, orally treated with Porphyromonas gingivalis (Pg), we screened for Pg-specific peptides in intestinal fecal specimens and examined whether Pg localization affected the intestinal microbiota profile altering gut metabolite levels. Finally, we screened whether deterioration of fasting hyperglycemia was related to changes in intrahepatic glucose metabolism, using proteome and metabolome analyses. As results; (1) Oral Pg treatment aggravated both fasting and postprandial hyperglycemia (P < 0.05) with a significant (P < 0.01) increase in dental alveolar bone resorption. (2) Pg-specific peptides were identified in fecal specimens after oral Pg treatment and intestinal Pg profoundly altered gut microbiome profiles at the phylum, family, and genus levels. Prevotella showed the largest increase in abundance. Furthermore, Pg-treatment significantly altered intestinal metabolite levels. (3) Fasting hyperglycemia was associated with increases in gluconeogenesis-related enzyme and metabolite levels without changes in proinflammatory cytokine expressions and insulin resistance. This work reveals that oral Pg administration induced gut microbiota changes, leading to entero-hepatic metabolic derangements, thereby aggravating hyperglycemia in an obese type 2 diabetes mouse model.

scholarly journals Porphyromonas gingivalis induces entero-hepatic metabolic derangements with alteration of gut microbiota in a type 2 diabetes mouse model

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yoichiro Kashiwagi ◽  
Shunsuke Aburaya ◽  
Naoyuki Sugiyama ◽  
Yuki Narukawa ◽  
Yuta Sakamoto ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Mouse Model ◽  
Gut Microbiota ◽  
Porphyromonas Gingivalis ◽  
Alveolar Bone ◽  
Postprandial Hyperglycemia ◽  
Periodontal Pathogens ◽  
Periodontal Infection ◽  
Diabetes Mouse

AbstractPeriodontal infection induces systemic inflammation; therefore, aggravating diabetes. Orally administered periodontal pathogens may directly alter the gut microbiota. We orally treated obese db/db diabetes mice using Porphyromonas gingivalis (Pg). We screened for Pg-specific peptides in the intestinal fecal specimens and examined whether Pg localization influenced the intestinal microbiota profile, in turn altering the levels of the gut metabolites. We evaluated whether the deterioration in fasting hyperglycemia was related to the changes in the intrahepatic glucose metabolism, using proteome and metabolome analyses. Oral Pg treatment aggravated both fasting and postprandial hyperglycemia (P < 0.05), with a significant (P < 0.01) increase in dental alveolar bone resorption. Pg-specific peptides were identified in fecal specimens following oral Pg treatment. The intestinal Pg profoundly altered the gut microbiome profiles at the phylum, family, and genus levels; Prevotella exhibited the largest increase in abundance. In addition, Pg-treatment significantly altered intestinal metabolite levels. Fasting hyperglycemia was associated with the increase in the levels of gluconeogenesis-related enzymes and metabolites without changes in the expression of proinflammatory cytokines and insulin resistance. Oral Pg administration induced gut microbiota changes, leading to entero-hepatic metabolic derangements, thus aggravating hyperglycemia in an obese type 2 diabetes mouse model.

Hypoglycaemic effect of catalpol in a mouse model of high-fat diet-induced prediabetes

2020 ◽  
Vol 45 (10) ◽  
pp. 1127-1137 ◽  
Author(s):  
Dengqiu Xu ◽  
Xiaofei Huang ◽  
Hozeifa M. Hassan ◽  
Lu Wang ◽  
Sijia Li ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Skeletal Muscle ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Sensitivity ◽  
Glucose Tolerance ◽  
Mouse Model ◽  
Fasting Glucose ◽  
Hypoglycaemic Effect

Type 2 diabetes mellitus is a major health problem and a societal burden. Individuals with prediabetes are at increased risk of type 2 diabetes mellitus. Catalpol, an iridoid glycoside, has been reported to exert a hypoglycaemic effect in db/db mice, but its effect on the progression of prediabetes is unclear. In this study, we established a mouse model of prediabetes and examined the hypoglycaemic effect, and the mechanism of any such effect, of catalpol. Catalpol (200 mg/(kg·day)) had no effect on glucose tolerance or the serum lipid level in a mouse model of impaired glucose tolerance-stage prediabetes. However, catalpol (200 mg/(kg·day)) increased insulin sensitivity and decreased the fasting glucose level in a mouse model of impaired fasting glucose/impaired glucose tolerance-stage prediabetes. Moreover, catalpol increased the mitochondrial membrane potential (1.52-fold) and adenosine triphosphate content (1.87-fold) in skeletal muscle and improved skeletal muscle function. These effects were mediated by activation of the insulin receptor-1/glucose transporter type 4 (IRS-1/GLUT4) signalling pathway in skeletal muscle. Our findings will facilitate the development of a novel approach to suppressing the progression of diabetes at an early stage. Novelty Catalpol prevents the progression of prediabetes in a mouse model of prediabetes. Catalpol improves insulin sensitivity in skeletal muscle. The effects of catalpol are mediated by activation of the IRS-1/GLUT4 signalling pathway.

scholarly journals Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes

Diabetologia ◽  
2009 ◽  
Vol 52 (8) ◽  
pp. 1647-1655 ◽  
Author(s):  
E. O. List ◽  
A. J. Palmer ◽  
D. E. Berryman ◽  
B. Bower ◽  
B. Kelder ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Hormone ◽  
Body Composition ◽  
Blood Glucose ◽  
Glucose Tolerance ◽  
Mouse Model ◽  
Fasting Blood Glucose ◽  
Diet Induced Obesity

Molecular and cellular bases of diabetes: Focus on type 2 diabetes mouse model-TallyHo

2019 ◽  
Vol 1865 (9) ◽  
pp. 2276-2284 ◽  
Author(s):  
Kavya Tamarai ◽  
Jasvinder Singh Bhatti ◽  
P. Hemachandra Reddy
Keyword(s):  
Type 2 Diabetes ◽  
Mouse Model ◽  
Diabetes Mouse

scholarly journals LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes

Diabetologia ◽  
2015 ◽  
Vol 59 (3) ◽  
pp. 634-643 ◽  
Author(s):  
Megan V. Cannon ◽  
Herman H. W. Silljé ◽  
Jürgen W. A. Sijbesma ◽  
Mohsin A. F. Khan ◽  
Knut R. Steffensen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Tolerance ◽  
Mouse Model ◽  
Cardiac Hypertrophy

scholarly journals Lipid‐lowering effect on glucose metabolism in the type 2 diabetes mouse model of TALLYHO/Jng

2006 ◽  
Vol 20 (4) ◽  
Author(s):  
Jennifer M. Fortuna ◽  
Ola A. Mostafa ◽  
Taryn P. Stewart ◽  
Jung Han Kim
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Metabolism ◽  
Mouse Model ◽  
Lipid Lowering ◽  
Lowering Effect ◽  
Lipid Lowering Effect ◽  
Diabetes Mouse

Structural analysis of tooth and jawbone in a type 2 diabetes mouse model

2014 ◽  
Author(s):  
Felix Repp ◽  
Philip Kollmannsberger ◽  
Andreas Roschger ◽  
Paul Roschger ◽  
Wolfgang Wagermaier ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Structural Analysis ◽  
Mouse Model ◽  
Diabetes Mouse
Sign in / Sign up

Export Citation Format

Share Document